Shares of weight loss and diabetes medication maker Novo Nordisk (NYSE: NVO) have slumped precipitously over the past 52 ...

A new study suggests popular weight-loss drugs like Ozempic and Zepbound may be linked to rare eye conditions that could ...

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s ...

Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions.

Beyond treating diabetes and helping people lose weight, GLP-1s may also improve libido. But the reasons are as complex as ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Eli Lilly has been a terrific stock to own for the past five years, thanks to its excellent clinical and regulatory progress.

After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...